Summary
Boston Scientific Corporation (BSX) reported significant progress in its 2017 fiscal year, demonstrating robust revenue growth driven by strong performance across its diverse product portfolio. The company's strategic imperatives, including strengthening category leadership and expanding into high-growth adjacencies, appear to be yielding positive results, as evidenced by increases in net sales across multiple business segments like Interventional Cardiology, Peripheral Interventions, and MedSurg. Acquisitions, such as Symetis SA and EndoChoice Holdings, Inc., also contributed to this growth, with ongoing integration efforts expected to further enhance market position. Financially, BSX navigated a complex market, managing expenses effectively while continuing to invest in research and development. While the company reported a net income of $104 million ($0.08 per diluted share) on a GAAP basis, adjusted net income (excluding certain charges and credits) was significantly higher at $1.752 billion ($1.26 per diluted share), highlighting the impact of significant non-recurring items, including litigation-related charges and the Tax Cuts and Jobs Act. The company maintained investment-grade credit ratings and demonstrated strong cash flow from operations, supporting its liquidity and capital resource needs. Investors should note the substantial ongoing litigation reserves and the company's strategic focus on innovation and market expansion.
Financial Highlights
50 data points| Revenue | $9.05B |
| Cost of Revenue | $2.59B |
| Gross Profit | $6.46B |
| SG&A Expenses | $3.29B |
| Operating Expenses | $5.17B |
| Operating Income | $1.28B |
| Interest Expense | $229.00M |
| Net Income | $104.00M |
| EPS (Basic) | $0.08 |
| EPS (Diluted) | $0.08 |
| Shares Outstanding (Basic) | 1.37B |
| Shares Outstanding (Diluted) | 1.39B |
Key Highlights
- 1Net sales increased by 7.9% to $9.048 billion in 2017, driven by growth in key segments like Interventional Cardiology, Peripheral Interventions, and MedSurg.
- 2Acquisitions, including Symetis SA and EndoChoice Holdings, Inc., contributed to revenue growth and portfolio expansion.
- 3GAAP net income was $104 million ($0.08 per diluted share), while adjusted net income (excluding certain charges) was $1.752 billion ($1.26 per diluted share), indicating significant non-recurring items impacting reported net income.
- 4Research and Development expenses increased by 8% to $997 million, underscoring the company's commitment to innovation and future growth.
- 5The company maintained investment-grade credit ratings, with cash provided by operating activities reaching $1.426 billion, demonstrating solid cash flow generation.
- 6Significant litigation-related charges were recorded, with reserves totaling $1.612 billion as of December 31, 2017, highlighting a key risk factor.
- 7The company's strategic focus includes strengthening category leadership and expanding into high-growth adjacencies, supported by investments in R&D and strategic acquisitions.